Adocia announces the positive results of a study on BioChaperone Lispro – 29/12/2022 at 08:38

(AOF) – Adocia, a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, today announces new positive results for insulin BioChaperone Lispro (called THDB0206 in China) with his partner Tonghua Dongbao. BioChaperone Lispro was compared to Humalog (insulin lispro) and the pharmacokinetics and pharmacodynamics of BioChaperone Lispro were significantly faster.

Furthermore, BioChaperone Lispro has confirmed its good tolerance and safety profile.

“These results demonstrate once again the robustness of our technology and the advantages of our product compared to the most widely used rapid-acting insulin in the world”, declared Olivier Soula, Deputy CEO of Adocia. “We thank our partner Tonghua Dongbao for his rigor in the execution of the clinical development plan and in particular the Phase 3 studies currently in progress”.

Conducted in parallel to Phases 3, this Phase 1 study consisted of a randomized, controlled, open-label, crossover trial to evaluate the pharmacokinetics and pharmacodynamics of a single dose of BioChaperone Lispro in healthy Chinese volunteers. The main objective of this study was to evaluate the faster absorption and pharmacodynamic action of BioChaperone Lispro compared to an injection of insulin lispro.

Adocia has licensed BioChaperone Lispro to Tonghua Dongbao for China and other Asian territories which represent 200 million people with diabetes and an estimated 20 million of whom use insulin daily to survive.

In 2021, the Chinese insulin market was worth more than $5 billion.


Find out more about the “pharmacy” sector

Loss of speed in European research

European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.

Source link -86